A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors

Endocrine Connections

Volumn 3, Issue 4, 2014, Pages 215-223

  Modlin, Irvin M ^a   Aslanian, Harry ^b   Bodei, Lisa ^a,b   Drozdov, Ignat ^a   Kidd, Mark ^a  

^a Wren Laboratories   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Carcinoid; Chromogranin A; Gastroenteropancreatic; Multigene transcript; NET; Neuroendocrine; PCR; Proton pump inhibitor

Indexed keywords

CHROMOGRANIN A; PROTON PUMP INHIBITOR; SOMATOSTATIN;

ADULT; AGED; ARTICLE; CARCINOID; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TUMOR DIAGNOSIS;

EID: 84928954842     PISSN: None     EISSN: 20493614     Source Type: Journal    
DOI: 10.1530/EC-14-0100     Document Type: Article

References (54)

1. Modlin IM, Moss SF, Chung DC, Jensen RT & Snyderwine E. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. Journal of the National Cancer Institute 2008 100 1282–1289. (doi:10.1093/jnci/djn275)
2. Modlin IM, Latich I, Zikusoka M, Kidd M, Eick G & Chan AK. Gastrointestinal carcinoids: the evolution of diagnostic strategies. Journal of Clinical Gastroenterology 2006 40 572–582. (doi:10.1097/00004836-200608000-00003)
3. Turner GB, Johnston BT, McCance DR, McGinty A, Watson RG, Patterson CC & Ardill JE. Circulating markers of prognosis and responseto treatment in patients with midgut carcinoid tumours. Gut 2006 55 1586–1591. (doi:10.1136/gut.2006.092320)
4. Ardill JE & Erikkson B. The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut. Endocrine-Related Cancer 2003 10 459–462. (doi:10.1677/erc.0.0100459)
5. Meijer WG, Kema IP, Volmer M, Willemse PH & de Vries EG. Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. Clinical Chemistry 2000 46 1588–1596.
6. Metz DC & Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008 135 1469–1492. (doi:10.1053/j.gastro.2008.05.047)
7. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP et al. The current status of gastroenteropancreatic neuroendocrine tumors. Lancet Oncology 2008 9 61–72. (doi:10.1016/S1470-2045(07)70410-2)
8. Kanakis G & Kaltsas G. Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Best Practice & Research. Clinical Gastroenterology 2012 26 791–802. (doi:10.1016/j.bpg.2012.12.006)
9. Stridsberg M, Oberg K, Li Q, Stridsberg M, Eriksson B, Lundquist G & Skogseid B. Measurement of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. Journal of Endocrinology 1995 144 49–59. (doi:10.1677/joe.0.1440049)
10. Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B & Modlin IM. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinology and Metabolism Clinics of North America 2011 40 111–134. (doi:10.1016/j.ecl.2010.12.001)
11. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV & Kidd M. Chromogranin A – biological function and clinical utility in neuro endocrine tumor disease. Annals of Surgical Oncology 2010 17 2427–2443. (doi:10.1245/s10434-010-1006-3)
12. Marotta V, Nuzzo V, Ferrara T, Zuccoli A, Masone M, Nocerino L, Del Prete M, Marciello F, Ramundo V, Lombardi G et al. Limitations of chromogranin A in clinical practice. Biomarkers 2012 17 186–191. (doi:10.3109/1354750X.2012.654511)
13. Wu JT, Erickson AJ, Tsao KC, Wu TL & Sun CF. Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages. Annals of Clinical and Laboratory Science 2000 30 175–178.
14. Sciarra A, Monti S, Gentile V, Salciccia S, Gomez AM, Pannunzi LP & Di Silverio F. Chromogranin A expression in familial versus sporadic prostate cancer. Urology 2005 66 1010–1014. (doi:10.1016/j.urology. 2005.05.045)
15. Hsiao RJ, Mezger MS & O’Connor DT. Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney International 1990 37 955–964. (doi:10.1038/ki.1990.71)
16. Giusti M, Sidoti M, Augeri C, Rabitti C & Minuto F. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. European Journal of Endocrinology 2004 150 299–303. (doi:10.1530/eje.0.1500299)
17. Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U & Sandvik AK. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996 39 649–653. (doi:10.1136/gut.39.5.649)
18. de Souto Barreto P, Lapeyre-Mestre M, Mathieu C, Piau C, Bouget C, Cayla F, Vellas B & Rolland Y. Prevalence and associations of the use of proton-pump inhibitors in nursing homes: a cross-sectional study. Journal of the American Medical Directors Association 2013 14 265–269. (doi:10.1016/j.jamda.2012.10.018)
19. Gerson LB, Kahrilas PJ & Fass R. Insights into gastroesophageal reflux disease-associated dyspeptic symptoms. Clinical Gastroenterology and Hepatology 2011 9 824–833. (doi:10.1016/j.cgh.2011.05.015)
20. Curtis KA, Hanson DL, Kennedy MS & Owen SM. Evaluation of a multiplex assay for estimation of HIV-1 incidence. PLoS ONE 2013 8 e64201. (doi:10.1371/journal.pone.0064201)
21. Hood L & Tian Q. Systems approaches to biology and disease enable translational systems medicine. Genomics, Proteomics & Bioinformatics 2012 10 181–185. (doi:10.1016/j.gpb.2012.08.004)
22. Modlin I, Drozdov I & Kidd M. The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. PLoS ONE 2013 8 e63364. (doi:10.1371/journal.pone.0063364)
23. Modlin I, Drozdov I & Kidd M. Gut neuroendocrine tumor blood qPCR fingerprint assay: characteristics and reproducibility. Clinical Chemistry 2014 52 419–429. (doi:10.1515/cclm-2013-0496)
24. Modlin I, Drozdov I, Alaimo D, Callahan S, Teixeira N, Bodei L & Kidd M. A multianalyte PCR blood test outperforms single analyte ELISAs for neuroendocrine tumor detection. Endocrine-Related Cancer 2014 21 615–628. (doi:10.1530/ERC-14-0190)
25. Modlin I, Drozdov I & Kidd M. A multitranscript blood neuroendocrine tumor molecular signature to identify treatment efficacy and disease progress. Journal of Clinical Oncology 2013 31 (Suppl) A4137.
26. Lewis MA & Yao JC. Molecular pathology and genetics of gastrointestinal neuroendocrine tumours. Current Opinion in Endocrinology, Diabetes, and Obesity 2013 4 4.
27. Faltin B, Zengerle R & von Stetten F. Current methods for fluorescencebased universal sequence-dependent detection of nucleic acids in homogenous assays and clinical applications. Clinical Chemistry 2013 59 1567–1582. (doi:10.1373/clinchem.2013.205211)
28. Eastman PS, Manning WC, Qureshi F, Haney D, Cavet G, Alexander C & Hesterberg LK. Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. Journal of Pharmaceutical and Biomedical Analysis 2012 70 415–424. (doi:10.1016/j.jpba.2012.06.003)
29. Cornejo KM, Kandil D, Khan A & Cosar EF. Theranostic and molecular classification of breast cancer. Archives of Pathology & Laboratory Medicine 2014 138 44–56. (doi:10.5858/arpa.2012-0442-RA)
30. Lee JW & Hall M. Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2009 877 1259–1271. (doi:10.1016/j.jchromb.2008.11.022)
31. Raza A, Ali Z, Irfan J, Murtaza S & Shakeel S. Analytical variables influencing the HCV RNA determination by TaqMan real-time PCR in routine clinical laboratory practice. Molecular Biology Reports 2012 39 7421–7427. (doi:10.1007/s11033-012-1574-3)
32. Modlin IM, Gustafsson BI, Drozdov I, Nadler B, Pfragner R & Kidd M. Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors. Annals of Surgical Oncology 2009 16 487–498. (doi:10.1245/s10434-008-0251-1)
33. Fleige S, Walf V, Huch S, Prgomet C, Sehm J & Pfaffl MW. Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR. Biotechnology Letters 2006 28 1601–1613. (doi:10.1007/s10529-006-9127-2)
34. Hanley JA & McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983 148 839–843. (doi:10.1148/radiology.148.3.6878708)
35. Fink L, Seeger W, Ermert L, Hanze J, Stahl U, Grimminger F, Kummer W & Bohle RM. Real-time quantitative RT-PCR after laser-assisted cell picking. Nature Medicine 1998 4 1329–1333. (doi:10.1038/3327)
36. Ginzinger DG, Godfrey TE, Nigro J, Moore DH II, Suzuki S, Pallavicini MG, Gray JW & Jensen RH. Measurement of DNA copy number at microsatellite loci using quantitative PCR analysis. Cancer Research 2000 60 5405–5409.
37. Tohmola N, Itkonen O, Sane T, Markkanen H, Joenvaara S, Renkonen R & Hamalainen E. Analytical and preanalytical validation of a new mass spectrometric serum 5-hydroxyindoleacetic acid assay as neuroendocrine tumor marker. Clinica Chimica Acta 2013 428C 38–43. (doi:10.1016/j.cca.2013.1010.1025)
38. de Laat JM, Pieterman CR, Weijmans M, Hermus AR, Dekkers OM, de Herder WW, van der HorstSchrivers AN, Drent ML, Bisschop PH, Havekes B et al. Low accuracy of tumor markers for diagnosing pancreatic neuroendocrine tumors in multiple endocrine neoplasiatype 1 patients. Journal of Clinical Endocrinology and Metabolism 2013 98 4143–4151. (doi:10.1210/jc.2013-1800)
39. Stridsberg M, Eriksson B, Oberg K & Janson ET. A comparison between three commercial kits for chromogranin A measurements. Journal of Endocrinology 2003 177 337–341. (doi:10.1677/joe.0.1770337)
40. Verderio P, Dittadi R, Marubini E, Pizzamiglio S, Gion M, De Apollonia L & Paradiso A. An Italian program of external quality control for chromogranin A (CgA) assay: performance evaluation of CgA determination. Clinical Chemistry and Laboratory Medicine 2007 45 1244–1250. (doi:10.1515/CCLM.2007.251)
41. Portela-Gomes GM & Stridsberg M. Selective processing of chromogranin A in the different islet cells in human pancreas. Journal of Histochemistry and Cytochemistry 2001 49 483–490. (doi:10.1177/ 002215540104900408)
42. Stridsberg M, Eriksson B, Oberg K & Janson ET. A panel of 11 regionspecific radioimmunoassays for measurements of human chromogranin A. Regulatory Peptides 2004 117 219–227. (doi:10.1016/j.regpep. 2003.10.023)
43. Ramachandran R, Bech P, Murphy KG, Dhillo WS, Meeran KM, Chapman RS, Caplin M, Ghatei MA, Bloom SR & Martin NM. Improved diagnostic accuracy for neuroendocrine neoplasms using two chromogranin A assays. Clinical Endocrinology 2012 76 831–836. (doi:10.1111/j.1365-2265.2011.04319.x)
44. Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, Cherfi A & Oberg KE. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. Journal of Clinical Endocrinology and Metabolism 2011 98 3741–3749. (doi:10.1210/jc.2011-0666)
45. Anon. Biomarkers on a roll. Nature Biotechnology 2010 28 431. (doi:10.1038/nbt0510-431)
46. Palmer C, Duan X, Hawley S, Scholler N, Thorpe JD, Sahota RA, Wong MQ, Wray A, Bergan LA, Drescher CW et al. Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS ONE 2008 3 e2633. (doi:10.1371/journal.pone.0002633)
47. Abraham NS. Proton pump inhibitors: potential adverse effects. Current Opinion in Gastroenterology 2012 28 615–620. (doi:10.1097/MOG. 0b013e328358d5b9)
48. Ali T, Roberts DN & Tierney WM. Long-term safety concerns with proton pump inhibitors. American Journal of Medicine 2009 122 896–903. (doi:10.1016/j.amjmed.2009.04.014)
49. Sanduleanu S, Stridsberg M, Jonkers D, Hameeteman W, Biemond I, Lundqvist G, Lamers C & Stockbrugger RW. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case–control study. Alimentary Pharmacology & Therapeutics 1999 13 145–153. (doi:10.1046/j.1365-2036.1999.00466.x)
50. Fossmark R, Jianu CS, Martinsen TC, Qvigstad G, Syversen U & Waldum HL. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition. Scandinavian Journal of Gastroenterology 2008 43 20–24. (doi:10.1080/ 00365520701561959)
51. Mosli HH, Dennis A, Kocha W, Asher LJ & Van Uum SH. Effect of shortterm proton pump inhibitor treatment and its discontinuation on chromogranin A in healthy subjects. Journal of Clinical Endocrinology and Metabolism 2012 97 E1731–E1735. (doi:10.1210/jc.2012-1548)
52. Jianu CS, Fossmark R, Viset T, Qvigstad G, Sordal O, Marvik R & Waldum HL. Gastric carcinoids after long-term use of a proton pump inhibitor. Alimentary Pharmacology & Therapeutics 2012 36 644–649. (doi:10.1111/apt.12012)
53. Thariani R, Henry NL, Ramsey SD, Blough DK, Barlow B, Gralow JR & Veenstra DL. Is a comparative clinical trial for breast cancer tumor markers to monitor disease recurrence warranted? A value of information analysis. Journal of Comparative Effectiveness Research 2013 2 325–334. (doi:10.2217/cer.13.15)
54. Reinke T. NCCN endorses PSA testing in absence of better alternatives. Managed Care 2014 23 39–41.